12月31日，春立医疗今日收盘12.8元，下跌3.18%，滚动市盈率PE（当前股价与前四季度每股收益总和的比值）达到31.00倍。
从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.73倍，行业中值31.98倍，春立医疗排名第71位。
截至2024年三季报，共有8家机构持仓春立医疗，其中其他3家、基金3家、券商1家、保险1家，合计持股数3256.65万股，持股市值4.71亿元。
北京市春立正达医疗器械股份有限公司是国内领先的骨科医疗器械厂商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司主要产品为关节假体产品及脊柱类植入产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊柱类植入产品为脊柱内固定系统的全系列产品组合。公司获得过北京生物医药产业跨越发展工程（G20工程）-创新引领企业、医疗器械质量管理示范企业、COA2012最佳合作伙伴、安全生产标准化金安企业等诸多荣誉。
最新一期业绩显示，2024年三季报，公司实现营业收入5.08亿元，同比-35.84%；净利润6115.14万元，同比-66.14%，销售毛利率69.30%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.